Barrington raised the firm’s price target on Haemonetics (HAE) to $93 from $90 and keeps an Outperform rating on the shares after the company announced that it had acquired Vivasure Medical Limited, an Ireland-based developer of advanced polymer implants and delivery systems. The firm is increasing its price target based on a positive view of the Vivasure transaction, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE: